Hutchison China MediTech Dette/Equité
Quel est le Dette/Equité de Hutchison China MediTech?
Le Dette/Equité de Hutchison China MediTech Ltd. est 0.72
Quelle est la définition de Dette/Equité?
Le ratio d'endettement et d'équité est un ratio financier indiquant la proportion relative des capitaux propres et de la dette utilisée pour financer les actifs d'une entreprise.
The debt to equity ratio is generally calculated by dividing debt by equity. The D/E ratio is also known as risk, gearing or leverage. The two components are often taken from the firm's balance sheet or statement of financial position (so-called book value), but the ratio may also be calculated using market values for both, if the company's debt and equity are publicly traded, or using a combination of book value for debt and market value for equity financially. Preferred stock can be considered part of debt or equity. Attributing preferred shares to one or the other is partially a subjective decision but will also take into account the specific features of the preferred shares. When used to calculate a company's financial leverage, the debt usually includes only the long-term debt.
Dette/Equité des entreprises dans Health Care secteur sur LSE par rapport à Hutchison China MediTech
Que fait Hutchison China MediTech?
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases worldwide. It operates in two segments, Oncology/Immunology and Other Ventures. It manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical, and consumer health products. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), papillary and clear cell renal cell carcinoma, colorectal cancer (CRC), and gastric cancer (GC); and Fruquintinib, an inhibitor for CRC, breast cancer, GC, endometrial cancer (EMC), NSCLC, hepatocellular carcinoma, and gastrointestinal and solid tumors. It also develops Surufatinib, an inhibitor for neuroendocrine tumors (NET), pancreatic NET, non-pancreatic NET, biliary tract cancer, sarcoma, neuroendocrine neoplasm, esophageal cancer, small cell lung cancer, GC, thyroid cancer, EMC, NSCLC, and solid tumors; HMPL-523, an inhibitor for indolent non-Hodgkin's lymphoma (NHL), B-cell malignancies, and immune thrombocytopenic purpura; and HMPL-689 for indolent non-Hodgkin's, follicular, marginal zone, mantle cell, diffuse large B cell, chronic lymphocytic leukemia/small lymphocytic, and Hodgkin's lymphoma. The company develops HMPL-453, an inhibitor for intrahepatic cholangiocarcinoma; HMPL-306, an inhibitor for hematological malignancies, gliomas, and solid tumors; HMPL-295 for solid tumors; and HMPL-813 and HMPL-309 EGFR inhibitors. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, BeiGene, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics (Suzhou) Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Central, Hong Kong.
Entreprises avec dette/equité similaire à Hutchison China MediTech
- Informa Plc a Dette/Equité de 0.72
- Ashok Alco-Chem a Dette/Equité de 0.72
- YASKAWA Electric a Dette/Equité de 0.72
- Warehouses De Pauw SCA a Dette/Equité de 0.72
- Warehouses De Pauw NV a Dette/Equité de 0.72
- CyanConnode plc a Dette/Equité de 0.72
- Hutchison China MediTech a Dette/Equité de 0.72
- Universal Security Instruments a Dette/Equité de 0.72
- Zimmer Biomet Inc a Dette/Equité de 0.72
- Oriental Trimex a Dette/Equité de 0.72
- Buru a Dette/Equité de 0.72
- American Homes 4 Rent a Dette/Equité de 0.72
- Langham Hospitality Investments a Dette/Equité de 0.72